0001209191-16-147288.txt : 20161028 0001209191-16-147288.hdr.sgml : 20161028 20161028161030 ACCESSION NUMBER: 0001209191-16-147288 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161026 FILED AS OF DATE: 20161028 DATE AS OF CHANGE: 20161028 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: SUITE 400, 101 LINDENWOOD DRIVE CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-321-5554 MAIL ADDRESS: STREET 1: SUITE 400, 101 LINDENWOOD DRIVE CITY: MALVERN STATE: PA ZIP: 19355 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ali-Jackson Kamil CENTRAL INDEX KEY: 0001654337 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 161958707 MAIL ADDRESS: STREET 1: C/O ACLARIS THERAPEUTICS, INC. STREET 2: 101 LINDENWOOD DRIVE, SUITE 400 CITY: MALVERN STATE: PA ZIP: 19355 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-10-26 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001654337 Ali-Jackson Kamil C/O ACLARIS THERAPEUTICS, INC. 101 LINDENWOOD DRIVE, SUITE 400 MALVERN PA 19355 0 1 0 0 Chief Legal Officer Common Stock 2016-10-26 4 M 0 3912 1.52 A 79869 D Common Stock 2016-10-26 4 S 0 3912 21.83 D 75957 D Employee StockOption (right to buy) 1.52 2016-10-26 4 M 0 3912 0.00 D 2024-12-07 Common Stock 3912 6522 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2016. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.36 to $22.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. 25% of the shares underlying this option, representing a right to purchase a total of 10,434 shares, vested on December 8, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the issuer as of the applicable vesting date. /s/ Brian F. Leaf, Attorney-in-fact 2016-10-28